News

NICE and IQWiG nix Benlysta
Enlarge image

PolicyGermanyUK

NICE and IQWiG nix Benlysta

07.05.2012 - Healthcare cost watchdogs are not convinced by GSK’s Lupus drug Benlysta: British NICE and German IQWiG have recommended against the drug.

Cologne/London – “No additional benefit documented” – With these harsh words the German Institute for Quality and Efficiency in Health Care (IQWiG) rebuffed GSK’s Lupus antibody belimumab (Benlysta). Under the new, tougher German reimbursement regime, the Institute evaluates newly approved drugs for their additional medical benefit and issues a draft benefit assessment. That decision could mean a large, forced discount to Benlysta's price on the German market.

Although Benlysta is the first new treatment for lupus for decades, it has been slow to take off so far. Negative assessments as form NICE and IQWiG won’t help to improve the situation. GSK, Britain's biggest drugmaker, said on Thursday that the judgment from IQWiG was "completely inexplicable from a medical point of view and disregards genuine progress in therapy".

The drug was discovered by Human Genome Science (HGS) and developed jointly with GSK. In mid-April GSK offered to acquire the US-based biotech company for $2,3b. HGS’ management refused the offer, stating, it “does not reflect value inherent in company“.

„Their case for a higher bid seems to be based on the market potential of Benlysta, but the arguing has begun over how realistic those hopes are“, stated Drug discovery Chemist Derek Lowe. Besides Benlysta, HGS might bank on albiglutide (Diabetes) and darapladib (Artheroslcerosis), which are currently undergoing Phase III trials, which could bring significant revenues if approved.

http://www.european-biotechnology-news.com/news/news/2012-02/nice-and-iqwig-nix-benlysta.html

SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto to discuss a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

FinancingSwitzerlandUK

29.04.2015 Biopharma start-up CRISPR Therapeutics has raised US$64m to hurry the new CRISPR/Cas9 technology to the clinic.

FinancingBelgium

28.04.2015 After having raised €100m in its stock market debut, MDx company Biocartis has gained 13 percent on its first trading day.

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

FinancingUK

21.04.2015 Ahead of its listing on the London Stock Exchange, Woodford’s Patient Capital Trust has raised a record sum of €1.1bn. The fund met with immense interest by investors.

PoliticsEU

22.04.2015 A legislative proposal by the European Commission is set to renationalise market authorisation of genetically modified crops.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DFranceUKSweden

24.04.2015 AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS0.08 CHF14.29%
  • 4SC5.75 EUR6.28%
  • WILEX5.43 EUR3.43%

FLOP

  • CYTOS1.17 CHF-7.87%
  • MEDIGENE9.45 EUR-6.99%
  • FORMYCON24.99 EUR-5.02%

TOP

  • 4SC5.75 EUR285.9%
  • WILEX5.43 EUR78.0%
  • SARTORIUS151.95 EUR18.3%

FLOP

  • BIOTEST70.10 EUR-26.1%
  • MEDIGENE9.45 EUR-16.7%
  • CYTOS1.17 CHF-14.6%

TOP

  • SANTHERA93.40 CHF2294.9%
  • CYTOS1.17 CHF735.7%
  • WILEX5.43 EUR531.4%

FLOP

  • MOLOGEN4.79 EUR-56.5%
  • BIOFRONTERA2.39 EUR-26.2%
  • THERAMETRICS0.08 CHF-20.0%

No liability assumed, Date: 06.05.2015